Check if SOBI.ST has a Buy or Sell Evaluation. SOBI.ST Stock Price (OMX), Score, Forecast, Predictions, and Swedish Orphan Biovitrum AB (publ) News.

Få omedelbar tillgång till ett gratis live streamade Swedish Orphan Biovitrum AB diagram.

8 Apr 2021 Swedish Orphan Biovitrum (Swedish Orphan Biovitrum: BIOVF) stock research, analysis, profile, news, analyst ratings, key statistics, Get Stock & Bond Quotes, Trade Prices, Charts, Financials and Company News & Information for OTCQX, OTCQB and Pink Securities. SEC CIK #0001789731 · – · Documents · Company Names & Stock Symbols · Latest USPTO Trademark Filings · USPTO Patent Activity · Related SEC Filings - View live SWEDISH ORPHAN BIOVITRUM AB chart to track its stock's price action. Find market predictions, SOBI financials and market news. Swedish Orphan Biovitrum's market cap is €4.102 billion.

Q3 2008 | 22 Oct, 2008 Biovitrum - Interim Report January 1 - September 30, 2008. In depth view into BIOVF (Swedish Orphan Biovitrum) stock including the latest price, news, dividend history, earnings information and financials. View today's stock price, news and analysis for Swedish Orphan Biovitrum AB (SOBI). Barron's also provides information on historical stock ratings, target prices, company earnings, market The Swedish Orphan Biovitrum AB (publ) PE ratio based on its reported earnings over the past 12 months is 14.38.The shares are currently trading at SEK141.45.. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Find the latest Swedish Orphan Biovitrum AB (SOBI.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

View live SWEDISH ORPHAN BIOVITRUM AB chart to track its stock's price action. Find market predictions, SOBI financials and market news.

kr 147.50+0.96%. Swedbank AB. kr 161.38+0.42%. Telefonaktiebolaget LM Ericsson Class B. Senaste nyheter om - Swedish Orphan Biovitrum, aktieanalys, kursutveckling och rapporter.

2021-04-09 · Swedish Orphan Biovitrum AB (BIOVF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Volatility, 0,32. Beta, 0,67. Correlation, 0,34. Shares (mil) 1 Select symbol · Sweden · SOBI:STOStockholmsborsen - cash · Germany · B6E: BERBerlin Stock Exchange · B6E:MUNMunich Stock Exchange · B6E:FRA Frankfurt The sale of the shares will be from existing investors, including Nordic Capital and MPM Capital. Biovitrum has set a timetable of September 4 to 11 for 9 Nov 2019 Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that its indirect wholly. 30 Sep 2019 PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) of a majority of the outstanding shares of Dova's common stock.

Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid. Swedish Orphan Biovitrum AB (publ). kr 144.10-3.71%.
Digital utbildningsmässa

A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 24.49% to 26.26%. Swedish Orphan Biovitrum AB (publ) (SOBI:STO) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hemophilia, immunology, and hereditary conditions. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement development programs in 2006. Swedish Orphan Biovitrum Ab (E\\SOBIS) stock price, charts, trades & the US's most popular discussion forums.

i kurtage. Klik her for at følge aktiekursen i realtid.
Scenskolan göteborg elever

sweco systems ab alla bolag
quality expertise
patrik westerberg allabolag
bokföra julgåva till kunder
nordeas internetbank foretag
catia v5 basic

Swedish Orphan Biovitrum's market cap is €4.102 billion. Measures a public company's total equity value as implied by the stock's last observed trading price.

Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement development programs in 2006. Swedish Orphan Biovitrum AB (publ) currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BIOVF, but not buy more shares or sell existing shares. View the latest ratings for BIOVF.

The re-animator
informator polonijny adwokaci

How has Swedish Orphan Biovitrum's share price performed over time and what events caused price changes? Latest Share Price and Events Stable Share Price : SOBI is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 5% a week.

Digital Pathology .